11 completed, 2 terminated, 1 recruiting, 1 unknown. 12 Phase 1, 6 Phase 2, 2 Phase 3.
By phase and status
Follow mavorixafor: new trials by email Literature Review of mavorixafor trials Research Report on mavorixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function Mavorixafor - Hepatic Insufficiency Phase 1 Completed X4 Pharmaceuticals 39 2025-02-28 2026-07-15 Drug-Drug Interaction Potential of Mavorixafor Mavorixafor, Carbamazepine, Efavirenz - Healthy Participants Phase 1 Completed X4 Pharmaceuticals 38 2025-02-18 2025-07-01 A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections Mavorixafor, Placebo - Neutropenia Phase 3 Recruiting X4 Pharmaceuticals 176 2024-06-06 2026-08-06 A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders Mavorixafor - Neutropenia Phase 1 / Phase 2 Completed X4 Pharmaceuticals 32 2021-10-16 2025-08-06 A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC X4P-001 - Triple Negative Breast Cancer Phase 1 / Phase 2 Unknown Abbisko Therapeutics Co, Ltd 24 2021-07-21 2021-11-02 A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 Mavorixafor, Ibrutinib - Waldenstrom's Macroglobulinemia Phase 1 Completed X4 Pharmaceuticals 16 2020-04-30 2024-08-27 Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome Mavorixafor, Placebo - WHIM Syndrome Phase 3 Completed X4 Pharmaceuticals 31 2019-10-24 2026-07-06 Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma X4P-001, Nivolumab - Clear Cell Renal Cell Carcinoma Phase 1 / Phase 2 Terminated X4 Pharmaceuticals 9 2016-12-07 2022-12-29 A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome X4P-001 - WHIM Syndrome Phase 2 Completed X4 Pharmaceuticals 8 2016-12-01 2024-10-30 X4P-001 and Pembrolizumab in Patients With Advanced Melanoma X4P-001, Pembrolizumab - Melanoma Phase 1 Completed X4 Pharmaceuticals 16 2016-09-15 2020-07-07 Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma X4P-001, axitinib - Clear Cell Renal Cell Carcinoma Phase 1 / Phase 2 Completed X4 Pharmaceuticals 74 2016-04-27 2024-10-03 A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers X4P-001 - Healthy Phase 1 Terminated X4 Pharmaceuticals 15 2016-01-12 2018-12-07 A Study of AMD11070 in HIV-infected Patients Carrying X4-tropic Virus AMD11070 - HIV Infections, X4 Tropic Virus Phase 1 Completed Genzyme, a Sanofi Company 10 2005-10-01 2014-02-11 Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients AMD11070 - HIV Infections Phase 1 / Phase 2 Completed National Institute of Allergy and Infectious Diseases (NIAID) 6 2004-11-01 2021-11-09 Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men Ritonavir, AMD070 - HIV Infections Phase 1 Completed National Institute of Allergy and Infectious Diseases (NIAID) 44 2021-11-01
Conditions studied HIV Infections (3) · Carcinoma, Renal Cell (2) · Neutropenia (2) · WHIM syndrome (2) · Autoimmune Diseases (1) · Barth Syndrome (1) · Cohen syndrome (1) · Glycogen Storage Disease Id (1) · Hepatic Insufficiency (1) · Melanoma (1) · Neutropenia, Severe Congenital, Autosomal Recessive 3 (1) · Shwachman-Diamond Syndrome (1) · Triple Negative Breast Neoplasms (1) · Waldenstrom Macroglobulinemia (1)
Sponsors X4 Pharmaceuticals (11) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Abbisko Therapeutics Co, Ltd (1) · Genzyme, a Sanofi Company (1)
Countries United States (14) · Australia (3) · France (2) · Greece (2) · Hungary (2) · Israel (2) · Italy (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Belgium (1) · Canada (1)
Top investigators Lu Gan, MD, PhD (2) · Craig Hendrix, MD (1) · J L Zheng, Director (1) · Michael S. Saag, MD (1)
Results publications PMID 17452489 , PMID 18285477 , PMID 19193109 , PMID 32870250 , PMID 33507454 , PMID 36923305 , PMID 38643510
NIH funding 2019 (2), 2016 (1), 2023 (1)